Documented cause
Alto Pharmacy was founded in 2015 by Jamie Kaplan and Mattieu Gamache-Asselin in San Francisco. The concept was a technology-enabled pharmacy that combined prescription delivery with dedicated pharmacist support — the opposite of the anonymous, high-volume, low-touch model of chain pharmacy retail (CVS, Walgreens, Rite Aid). Alto would deliver medications to patients' homes, maintain ongoing pharmacist relationships, handle prior authorizations, manage refills proactively, and use technology to reduce the friction of managing complex medication regimens. The company raised $354M from investors including Andreessen Horowitz, Owl Rock Capital, and others. Alto operated in San Francisco, Los Angeles, Denver, and Seattle, with particular focus on complex specialty medications for chronic conditions including HIV, oncology, and transplant patients who most needed medication management support. The unit economics were fatal from the structure of the US pharmacy reimbursement system. Pharmacy Benefit Managers (PBMs) — the middlemen between drug manufacturers, insurers, and pharmacies — set the reimbursement rates that pharmacies receive for dispensing prescriptions. These rates are set for high-volume commodity dispensing and are insufficient to cover the added cost of delivery, pharmacist support, and technology infrastructure that Alto's model required. Alto charged patients directly for some services but could not cover the gap. The specialty medication market (where margins are somewhat better) was Alto's strongest segment but not large enough to cross-subsidize the broader model. In October 2023, Alto announced it was shutting down operations, closing across all markets with approximately 30 days notice. Approximately 300 employees lost their jobs. Patients with complex chronic conditions scrambled to transfer prescriptions to other pharmacies.
Alternative account: Alto Pharmacy built a tech-first pharmacy experience with same-day delivery, real-time insurance billing, and pharmacist consultations via app. The company raised $354M from SoftBank, Google Ventures, and others. But pharmacy economics in the US are brutal: reimbursement rates from pharmacy benefit managers (PBMs) are set algorithmically and squeezed annually, generic drug margins are razor-thin, and delivery costs add rather than reduce cost. Alto was paying retail delivery costs to provide a service at PBM-mandated reimbursement rates. The math never worked. Alto shut down operations in 2023.